Repair Biotechnologies achieves atherosclerotic plaque regression with mRNA therapy

Repair Biotechnologies has achieved a significant clinical milestone with REP-0004, a lipid nanoparticle encapsulating messenger RNA that delivers its payload exclusively to the liver via hepatocyte-specific receptors. Once inside liver cells, the mRNA generates a fusion protein that selectively degrades excess intracellular free cholesterol—a toxic byproduct that accumulates with age and obesity—triggering a feedback loop that extracts excess cholesterol from the body back to the liver, where it is intercepted and broken down. The result is dramatic and rapid regression of atherosclerotic plaque, which accounts for 27% of all human deaths and remains the cardinal failure of modern cardiovascular medicine: statins and PCSK9 inhibitors merely slow growth, they never reliably reverse it. The FDA has granted Repair orphan drug designation for homozygous familial hypercholesterolemia and eligibility in the Rare Disease Evidence Principles program, accelerating the path to approval. For longevity-focused readers, this represents the first intervention that promises not merely to stabilize but actively reverse accumulated cardiovascular damage.